Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Pfizer and UCB Announce Formation of New Company ‘Cyclofluidic’ to Accelerate Drug Discovery Process

Abstract:
UK Government's Technology Strategy Board to Invest in Cyclofluidic R&D

Pfizer and UCB Announce Formation of New Company ‘Cyclofluidic’ to Accelerate Drug Discovery Process

London, UK | Posted on October 21st, 2008

Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB today announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time. The UK Government's Technology Strategy Board has helped facilitate this innovative arrangement between Pfizer and UCB and will continue to support Cyclofluidic by co-funding its R&D.

The aim of Cyclofluidic is to develop technologies that automate and integrate processes known as flow chemistry and flow biology to help pharmaceutical companies shorten timelines within the drug development process.

Explaining the background to the Technology Strategy Board's support, its Chief Executive, Iain Gray, said: "Our role is to stimulate the development and deployment of technologies which, as well as benefiting society, also provide global business opportunities for the UK. Cyclofluidic is an excellent example of the private and public sectors working together to develop world-leading technologies which have the potential to bring enormous benefit to patients in the UK and around the world. We are delighted to offer our support and investment."

"Cyclofluidic's entry into the rapidly evolving microfluidic technology area has the potential to radically transform the medicinal chemistry and biology interface." Says Dr Neil Weir, Senior Vice President Research at UCB. "It's an exciting opportunity for UCB and Pfizer to collaborate and offers real potential for improved productivity, underlining our commitment to innovation for patients."

Dr Annette Doherty, Vice President and Research Head at Pfizer's European R&D Headquarters said "We are extremely pleased to collaborate with UCB and the Technology Strategy Board to help improve efficiency in the drug development process. We are excited by the potential of this new partnership to help us identify the most effective medicines for later stages of development and - ultimately - create new and improved therapies for patients."

Peter Luke, Senior Director, Worldwide Business Development at Pfizer said, "This is a great example of how public-private partnerships can provide innovative technologies to speed medicines to market. We are impressed by the way the Technology Strategy Board has initiated a novel and creative deal structure."

Cyclofluidic will be jointly owned by Pfizer and UCB, with each company having both a seat and scientific observer rights on the board.

Currently, it takes between 12-15 years and a cost of up to £500 million to develop a new medicine. One of the most time-intensive and skilful parts of pharmaceutical research is the screening of potential medicines against therapeutic targets.

Cyclofluidic will develop a microfluidic closed loop lead optimisation platform which will enable researchers to access state of the art expertise in flow chemistry, flow screening and microfluidic engineering. This will be addressed through extensive collaboration with key academics and component manufacturers

Cyclofluidic will also provide training for both flow chemistry and biology scientists at its facility, to be located in the South of England.

Pharmaceuticals in the UK

The UK has been a very successful location for the global pharmaceutical industry. It employs 73,000 people directly and generates another 250,000 jobs in related industries. The UK conducts more pharmaceutical R&D than any other EU country, and investment from pharmaceutical companies is critical to the UK's research base - around 25% of all industrial R&D comes from the sector.

####

About Pfizer Ltd
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. Pfizer also partners with healthcare providers, governments and local communities around the world to expand access to medicines and to provide better quality health care and health system support. At Pfizer, more than 84,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.

About UCB

UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).

About Technology Strategy Board

The Technology Strategy Board is a business-led executive non-departmental public body, established by the government. Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business, in order to increase economic growth and improve the quality of life. It is sponsored by the Department for Innovation, Universities and Skills (DIUS). For further information please visit www.innovateuk.org.

For more information, please click here

Contacts:
Pfizer
Lisa O’Neil, 00 44 1737 331536
or
UCB
Ian Weatherhead, 00 44 1753 447950
or
TSB
Nick Sheppard, 00 44 1793 442772

Copyright © Pfizer Ltd

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

'Lossless' metamaterial could boost efficiency of lasers and other light-based devices February 20th, 2017

Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017

Liquid metal nano printing set to revolutionize electronics: Creating integrated circuits just atoms thick February 18th, 2017

Engineers shrink microscope to dime-sized device February 17th, 2017

Nanomedicine

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017

Meta-lenses bring benchtop performance to small, hand-held spectrometer: Game-changing nanostructure-based lenses allow smaller devices, increased functionality February 9th, 2017

Announcements

'Lossless' metamaterial could boost efficiency of lasers and other light-based devices February 20th, 2017

Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017

Liquid metal nano printing set to revolutionize electronics: Creating integrated circuits just atoms thick February 18th, 2017

Engineers shrink microscope to dime-sized device February 17th, 2017

Alliances/Trade associations/Partnerships/Distributorships

Leti Coordinating Project to Adapt Obstacle-Detection Technology Used in Autonomous Cars for Portable and Wearable Systems: INSPEX to Combine Knowhow of Nine European Organizations to Create Portable and Wearable Spatial-Exploration Systems February 2nd, 2017

GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project